---

Analysis of cost variation among various statin preparations available in India

---

Original Article

Author Details : Padmavathi Vutukuru, Kranti Tekulapally*

Volume : 6, Issue : 1, Year : 2019

Article Page : 14-17

https://doi.org/10.18231/2393-9087.2019.0004

Suggest article by email

Get Permission

---

Abstract

Introduction: Hyperlipidemias are recognized as one of the major risk factors for the development of Coronary Artery Disease (CAD). Statins are the most potent lipid lowering agents currently available that significantly lower the morbidity and mortality associated with CAD.
Aim: To compare the cost of various statins of different brands by calculating the percentage variation of cost.
Materials and Methods: Prices of different statin preparations per 10 tablets/ capsules in rupees were reviewed from Drug today April-June 2018 issue and www.drugsupdate.com for analysis. Maximum and minimum price difference of the same drug manufactured by different pharmaceutical companies was calculated. Percentage variation was calculated as per the following formula

 Drug formulations manufactured by only one company and those whose price could not be obtained from the sources were excluded from analysis.
Results: Maximum companies are manufacturing single drug atorvastatin 10mg (192) and atorvastatin 5 mg + ezetimibe 10mg (40). Highest percentage variation in cost is found with atorvastatin 5 mg (900%) and in atorvastatin 10mg + amlodipine 5 mg (1488%).
Conclusion: There is wide variation in the cost of various statins available in India, which increases the economic burden on patients. Government of India should take more consumer friendly steps to control the cost of drugs. Physicians should maintain a P-drug list and prescribe low cost and effective drugs to improve compliance to drug therapy and ensure effective treatment of the disease.

Keywords: Statins, Cost variation, Hyperlipidemias.

How to cite : Vutukuru P, Tekulapally K, Analysis of cost variation among various statin preparations available in India. Indian J Pharm Pharmacol 2019;6(1):14-17

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.